🔬 What if you could make your aging mitochondria more numerous AND more powerful at the same time? A Japanese research team led by Gakushuin University has discovered "Mitorubin," a plant-derived compound that does exactly that. Built on a metabolite of berberine — the active ingredient in traditional East Asian herbs like goldthread and Amur cork tree — the compound improved heart function in 24-month-old mice and extended median lifespan by roughly 40% in obese mice. It's still animal-stage research, but it points to a path distinct from US longevity biotech, NAD+ supplements, and senolytics.

Boosting Both Quantity and Quality of Mitochondria

A research group at Gakushuin University in Tokyo, working with Kumamoto University, Japan Women's University, the Tokyo Metropolitan Institute for Geriatrics and Gerontology, the University of Tokyo, Jichi Medical University, Tokyo University of Pharmacy and Life Sciences, and Aoyama Gakuin University, has identified a new plant-derived compound that simultaneously increases both the number and the function of mitochondria. The findings were published on March 20, 2026, in npj Aging, an open-access journal in the Nature portfolio.

Mitochondria are the cellular organelles that produce ATP — the energy currency of life. With age, they decline both in number and in efficiency, and this decline is implicated in heart failure and a range of age-related diseases. Effective interventions that simultaneously address both the quantity and the quality of mitochondria have been elusive.

What set the Japanese team apart was their starting point: an enzyme called MITOL (also known as MARCHF5). MITOL is a mitochondrial ubiquitin ligase that regulates mitochondrial dynamics and quality control. The team's earlier work had shown that MITOL expression declines with age, and that mice engineered to lack MITOL specifically in heart muscle cells develop premature cardiac aging. So they built a screen looking for compounds that increase MITOL expression — a different angle from most aging research.

Goldthread and Amur Cork Tree: Clues from Traditional Medicine

The team tested numerous herbal extracts and known mitochondria-active compounds on human dermal fibroblasts. Two extracts stood out: Coptis japonica (goldthread, known in Japan as ouren) and Phellodendron amurense (Amur cork tree, kihada). Both are traditional East Asian herbal medicines used for centuries — primarily as anti-diarrheal agents — and both are rich in an alkaloid called berberine. Each extract roughly tripled MITOL mRNA expression.

Here's where the story gets interesting. When the researchers gave berberine itself to mouse muscle cells, MITOL expression did not go up. Instead, it was berberrubine, a major in-vivo metabolite of berberine produced after the body processes it, that strongly induced MITOL and other mitochondrial proteins.

In other words, the active agent isn't the famous compound everyone studies — it's what the body turns berberine into.

Solving the Solubility Problem with Acetic Acid

There was a major obstacle. The active form of berberrubine (the quinoid type) is essentially insoluble in water. Even 1,000 mL of water couldn't dissolve a small amount of it. That makes oral dosing and formulation extraordinarily difficult.

The team tried various Brønsted acids to form salts. Acetic acid produced a surprising result. When acetic acid was added to powdered berberrubine, a yellow solid formed that incorporated four molecules of acetic acid — a "berberrubine acetic acid adduct." Its water solubility was approximately 1 gram per milliliter — essentially completely soluble. Further drying produced a reddish-brown "berberrubine acetic acid salt" with one acetic acid per molecule, which dissolved at about 30 mg/mL.

The team named the family of compounds — quinoid-type berberrubine, the acetic acid salt, and the acetic acid adduct — collectively as "Mitorubin." With a water-soluble form available, animal experiments using berberrubine in drinking water became feasible.

What Happens at the Cellular Level

In cell experiments, Mitorubin increased not just MITOL but a whole panel of mitochondrial proteins (Tom20, Mfn2 on the outer membrane; HSP60 in the matrix; ATP5a in the inner membrane), in a dose-dependent manner. Mitochondrial DNA copy number also increased — meaning new mitochondria were being made (mitochondrial biogenesis).

When researchers stained mitochondria and looked at them under a microscope, treated cells showed elongated mitochondria. Functionally, oxygen consumption rate (OCR) rose across the board: basal respiration, ATP-linked respiration, and maximal respiratory capacity were all significantly higher.

Crucially, the effect appeared to be an adaptive response rather than damage. Reactive oxygen species (ROS) rose modestly, but antioxidant gene expression rose alongside. The researchers framed this as a textbook mitohormesis response — the phenomenon where mild mitochondrial stress triggers compensatory adaptations that ultimately improve cellular fitness. Caloric restriction and exercise are believed to work through similar mechanisms, and metformin has been suggested to as well.

In Aged Mice: Restored Heart Function. In Obese Mice: 40% Longer Median Lifespan

To test whether Mitorubin works in living animals, the team gave 24-month-old male C57BL/6N mice (the murine equivalent of elderly) drinking water containing 0.5 mg/mL of the berberrubine acetic acid adduct for 12 weeks. Echocardiography revealed that age-related left ventricular dilation, systolic dysfunction, and diastolic dysfunction were all attenuated in the treated group. Cardiac hypertrophy (measured by heart-weight to tibia-length ratio) and pulmonary congestion (lung-weight to tibia-length ratio) were both improved. Heart-failure markers (Nppa, Nppb, Myh7) and fibrosis markers (Collagen1a1, Ctgf) were lower than in controls.

For lifespan, the team tested two models. In normally aged mice starting treatment at 86 weeks, Mitorubin did not extend lifespan — but it didn't shorten it either, indicating no toxicity over chronic administration. In a high-fat-diet model where mice had been on HFD32 since 8 weeks of age and started Mitorubin at 60 weeks, the treated group showed a statistically significant extension of median lifespan, roughly 40% longer than controls.

The researchers explain the discrepancy: in C57BL/6 mice on a normal diet, age-associated death is dominated by tumors, where heart improvements don't translate into survival gains. But chronic high-fat diet causes broad cardiac pathology — lipid overload, mitochondrial dysfunction, fibrosis, hypertrophy, electrophysiological instability. Under that metabolic stress, protecting the heart actually saves lives.

How This Differs from US Longevity Biotech

To understand Mitorubin's place in aging research, it helps to compare it to the major international approaches.

Cellular reprogramming (the Altos Labs approach). Silicon Valley-based Altos Labs launched in 2022 with around $3 billion in funding — reportedly including investment from Jeff Bezos — to pursue "partial reprogramming" of cells using Yamanaka factors, building on Kyoto University Professor Shinya Yamanaka's iPS cell research. Calico Life Sciences, founded by Google's parent company Alphabet, works in adjacent territory. In 2025, AbbVie ended its long-term collaboration with Calico, and senolytic pioneer Unity Biotechnology shuttered in September 2025. These reprogramming approaches are technically sophisticated but remain mostly preclinical.

NAD+ precursor supplements. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors to NAD+, a coenzyme that declines with age. A 2026 randomized trial published in Nature Metabolism showed that 1 g/day of NMN or NR for 14 days approximately doubles circulating NAD+ levels. However, human trials show reliable NAD+ increases but limited functional gains in cognition, vascular function, or muscle strength in older adults. NMN's regulatory status is also contested in the US, where the FDA has questioned its sale as a dietary supplement.

Senolytics. The leading senolytic regimen combines dasatinib (a leukemia drug) and quercetin (a flavonoid) — "D+Q" — to selectively eliminate senescent cells. Dasatinib and quercetin together have been shown to selectively clear senescent cells in culture in both humans and animal models, and preclinical work has shown reduction in cortical neurofibrillary tangles in tau transgenic mouse models. Trials are ongoing in Alzheimer's, diabetes, and cardiovascular conditions.

Mitorubin. The Japanese compound's distinctive features are: (1) it boosts both quantity and function of mitochondria simultaneously, (2) it's derived from a plant metabolite, (3) it's orally bioavailable thanks to the acetic acid solubility breakthrough, and (4) it targets a specific mitochondrial ubiquitin ligase (MITOL) rather than a more diffuse pathway. It's neither NAD-replacement nor senescent-cell-clearance — it's a third route, "directly activating mitochondrial biogenesis and dynamics."

What's Still Unknown — and the Animal-Stage Caveat

It can't be stressed enough: this is a mouse study. The authors are explicit that human efficacy is not established. The compound's pharmacokinetic profile in human liver microsomes was actually more favorable than in mouse — higher metabolic stability, more free unbound compound in plasma — which suggests potential human efficacy at lower doses, but suggesting and demonstrating are different things. Clinical trials are required.

Several mechanistic questions also remain open. The exact transcriptional pathway by which Mitorubin upregulates MITOL is not fully characterized — the team showed it's not primarily through the KLF4–CBP/p300 axis. The compound also increases mitochondrial DNA content even in MITOL-knockout cells, indicating MITOL is not the only target. Possible interactions with the mitochondrial calcium uniporter (MCU), which berberine is known to bind, also need investigation.

The team has begun exploratory studies in skeletal muscle (relevant to sarcopenia and frailty) and in models of Alzheimer's and Parkinson's disease, given that mitochondrial dysfunction features prominently in both.

What makes the result noteworthy isn't a claim of imminent human therapeutics. It's that a metabolite of a compound used in East Asian medicine for centuries — repackaged as a water-soluble salt through a clever acetic acid trick — turns out to simultaneously upregulate mitochondrial biogenesis, improve mitochondrial dynamics, enhance respiration, restore aged hearts, and extend lifespan under metabolic stress. That's a different shape of story from the spectacular cellular-reprogramming startups and the NAD+ supplement market. A quieter, more pharmacologically grounded approach, coming from Japanese academic labs.

What approaches to aging are getting attention in your country right now? Are NMN, senolytics, or resveratrol-based supplements popular? And how do you feel about traditional herbal compounds being repurposed into modern medicine? Share your thoughts in the comments.

References